GANAB and myeloid sarcoma: These findings pertaining to the effect of ER-stress inhibitors are in congruence with human MS studies on GANAB, the enzymatic subunit involved in the UPR; as mentioned earlier, downregulation of GANAB is demonstrated in MS patients treated by IFNβ, an effect further enhanced by treatment-responsiveness [46].